Items where authors include "Fradette, S."

Article

Lovett, A., Chary, S., Babu, S. et al. (15 more authors) (2025) Serious neurologic adverse events in Tofersen clinical trials for amyotrophic lateral sclerosis. Muscle & Nerve, 71 (6). pp. 1006-1015. ISSN 0148-639X

van den Berg, L.H., Rothstein, J.D., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (26 more authors) (2024) Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. The Lancet Neurology, 23 (9). pp. 901-912. ISSN 1474-4422

Miller, T.M., Cudkowicz, M.E., Genge, A. et al. (23 more authors) (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal of Medicine, 387 (12). pp. 1099-1110. ISSN 0028-4793

Shaw, P. orcid.org/0000-0002-8925-2567, Miller, T., Cudkowicz, M. et al. (7 more authors) (2022) Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results. Journal of Neurology, Neurosurgery & Psychiatry, 93 (9). e2. ISSN 0022-3050

Miller, T., Cudkowicz, M., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (28 more authors) (2020) Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383 (2). pp. 109-119. ISSN 0028-4793